Signe Højstrup

Signe Højstrup

Auto-generated profile, based on publicly available information

Signe Højstrup

Department of Gynaecology, Fertility and Obstetrics, Juliane Marie Center Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
SHSigne Højstrup
Signe Højstrup
KHKim W. Hansen
Kim W. Hansen
UTUlrik Talleruphuus
Ulrik Talleruphuus
LMLisbeth Marner
Lisbeth Marner
LBLouise Bjerking
Louise Bjerking
EPEva Prescott
Eva Prescott
BACKGROUND: Rubidium-82 positron emission tomography ( 82 Rb PET) myocardial perfusion imaging is used in clinical practice to quantify regional perfusion defects. Additionally, 82 Rb PET provides a measure of absolute myocardial flow reserve (MFR), describing the vasculature state of health. We assessed whether 82 Rb PET-derived MFR is associated with all-cause mortality independently of the extent of perfusion defects. METHODS: We conducted a multicenter clinical registry-based study of patients undergoing 82 Rb PET myocardial perfusion imaging on suspicion of chronic coronary syndromes. Patients were followed up in national registries for the primary outcome of all-cause mortality. Global MFR ≤2 was considered reduced. RESULTS: Among 7169 patients studied, 38.1% were women, the median age was 69 (IQR, 61–76) years, and 39.0% had MFR ≤2. A total of 667 (9.3%) patients died during a median follow-up of 3.1 (IQR, 2.6–4.0) years, more in patients with MFR ≤2 versus MFR >2 (15.7% versus 5.2%; P <0.001). MFR ≤2 was associated with all-cause mortality across subgroups defined by the extent of perfusion defects (all P <0.05). In a Cox survival regression model adjusting for sex, age, comorbidities, kidney function, left ventricular ejection fraction, and perfusion defects, MFR ≤2 was a robust predictor of mortality with a hazard ratio of 1.62 (95% CI, 1.31–2.02; P <0.001). Among patients with no reversible perfusion defects (n=3101), MFR ≤2 remained strongly associated with mortality (hazard ratio, 1.86 [95% CI, 1.26–2.73]; P <0.01). The prognostic value of impaired MFR was similar for cardiac and noncardiac death. CONCLUSIONS: MFR ≤2 predicts all-cause mortality independently of the extent of perfusion defects. Our results support the inclusion of MFR when assessing the prognosis of patients suspected of chronic coronary syndromes.

4 October 2023 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
SHSigne Højstrup
Signe Højstrup
JTJakob Hartvig Thomsen
Jakob Hartvig Thomsen
EPEva Prescott
Eva Prescott
The Nordic countries, including Denmark, Finland, Iceland, Norway, and Sweden have seen a steep decline in cardiovascular mortality in recent decades. They are among the most egalitarian countries by several measures, and all have universal, publicly funded welfare systems providing healthcare for all citizens. However, despite these seemingly ideal conditions, disparities in access to cardiovascular care and outcomes persist. To address this challenge, The Lancet Region Health—Europe convened experts from a broad range of countries to summarize the current state of knowledge on cardiovascular disease disparities across Europe. This Series Paper presents the main challenges in Nordic countries based on evidence from high-quality nationwide registries. Focusing on major cardiovascular health determinants, areas in need of improvement were identified. There is a need for addressing structural causes underlying these disparities, such as poverty and discrimination, but also to improve access to healthcare in deprived neighborhoods and to address underlying social determinants of health that may mitigate disparities in cardiovascular outcomes. Overall, while the Nordic countries have made great strides in promoting egalitarianism and providing universal healthcare, there is still much work to be done to ensure equitable access to care and improved cardiovascular outcomes for all members of society.

20 June 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
SHSigne Højstrup
Signe Højstrup
KHKim W. Hansen
Kim W. Hansen
UTUlrik Talleruphuus
Ulrik Talleruphuus
LMLisbeth Marner
Lisbeth Marner
SGSøren Galatius
Søren Galatius
EPEva I. B. Prescott
Eva I. B. Prescott
Background: Coronary microvascular disease (CMD) may be part of a systemic small vessel disease that also manifests as neurological impairment and kidney disease. However, clinical evidence supporting a potential link is scarce. We assessed whether CMD is associated with an increased risk of small vessel disease in the kidney and brain. Methods and Results: A retrospective multicenter (n=3) study of patients clinically referred to 82‐rubidium positron emission tomography myocardial perfusion imaging was conducted between January 2018 and August 2020. Exclusion criterion was reversible perfusion defects >5%. CMD was defined as myocardial flow reserve (MFR) ≤2. The primary outcome, microvascular event, was defined by hospital contact for chronic kidney disease, stroke, or dementia. Among 5122 patients, 51.7% were men, median age 69.0 [interquartile range, 60.0–75.0] years, 11.0% had left ventricular ejection fraction ≤40%, and 32.4% had MFR ≤2. MFR was associated with baseline estimated glomerular filtration rate after multivariable adjustment ( β =0.04 [95% CI, 0.03–0.05]; P 2 (11.6% versus 5.5%, P <0.001). MFR ≤2 was associated to outcome with a hazard ratio (HR) of 2.30 (95% CI, 1.88–2.81, P <0.001) and an adjusted HR of 1.62 (95% CI, 1.32–2.00, P <0.001). Results were consistent across subgroups defined by presence of irreversible perfusion defects, estimated glomerular filtration rate, diabetes, left ventricular ejection fraction, and previous revascularization. Conclusions: This is the first large‐scale cohort study to link CMD to microvascular events in the kidney and brain. Data support the hypothesis that CMD is part of a systemic vascular disorder.

15 February 2024 in International Journal of Cardiology
Verified
Journal Article
Open access
MTM.H. Toftholm
M.H. Toftholm
SHS. Højstrup
S. Højstrup
UTU. Talleruphuus
U. Talleruphuus
LML. Marner
L. Marner
LBL. Bjerking
L. Bjerking
KSK.W. Skak-Hansen
K.W. Skak-Hansen
Finding patients with chronic coronary syndromes (CCS) whom revascularization could benefit, is complicated. Myocardial flow reserve (MFR), a measurement of myocardial perfusion, has proven prognostic value on survival and risk of major adverse cardiac events (MACE). We investigated if MFR identifies who may benefit from revascularization. Among 7462 patients from Danish hospitals examined with 82Rb PET between January 2018 and August 2020, patients with ≥5% reversible perfusion defects were followed for MACE and all-cause mortality. Associations between revascularisation (within 90 days) and outcomes according to MFR (< and ≥ 2) was assessed by Cox regression adjusted by inverse probability weighting for demographics, cardiovascular risk factors, comorbidities, and 82Rb PET variables. Of 1806 patients with ≥5% reversible perfusion defect, 893 (49%) had MFR < 2 and 491 underwent revascularisation (36.6% in MFR < 2 versus 17.9% MFR ≥ 2, p < 0.001). During a median follow-up of 37.0 [31.0-45.8 IQR] months, 251 experienced a MACE and 173 died. Revascularisation was associated with lower adjusted risk of all-cause mortality (hazard ratio [HR], 0.51 [95% CI, 0.30-0.88], p = 0.015) and MACE (HR, 0.54 [0.33-0.87], p = 0.012) in patients with MFR < 2 but not MFR ≥ 2 for all-cause mortality (HR 1.33 [0.52-3.40], p = 0.542) and MACE (HR 1.50 [0.79-2.84], p = 0.211). MFR significantly modified the association between revascularisation and MACE, but not all-cause mortality (interaction p-value 0.021 and 0.094, respectively). Revascularization was associated with improved prognosis among patients with impaired MFR. No association was seen in patients with normal MFR. In patients with regional ischemia, MFR may identify patients with a prognostic benefit from revascularization.

29 July 2026 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
SBSigne Højstrup Bessing
Signe Højstrup Bessing
MHMaria Guldbrandt Hauge
Maria Guldbrandt Hauge
JLJesper James Linde
Jesper James Linde
MJMarianne Johansen
Marianne Johansen
AEAnne Ersbøll
Anne Ersbøll
PDPeter Damme
Peter Damme
Introduction: Preeclampsia is known to be associated with a two‐ to fourfold elevated risk of developing cardiovascular disease in the first 15 years following pregnancy. In this cross‐sectional study of 892 women with prior preeclampsia, we aimed to assess differences in circulating angiogenic biomarker concentrations according to CT‐assessed coronary atherosclerosis in women up to 28 years after an index pregnancy complicated by preeclampsia. Material and Methods: Women were identified from clinical databases consisting of data from all deliveries within the Capital Region of Denmark from 1995 onwards. Women with prior preeclampsia and a current age between 35 and 55 years were included from the CPH‐PRECIOUS cohort. The primary outcome was differences in circulating angiogenic biomarkers according to CT‐assessed coronary atherosclerosis. Results: The median time since the pregnancy complicated by preeclampsia was 12.5 years (range: 0–28 years). PlGF concentrations were significantly higher in women with coronary atherosclerosis (9.6 pg/mL [IQR 4.9–12.6] vs. 7.4 pg/mL [IQR 3.9–11.3], p = 0.001), and subsequently a lower calculated sFlt‐1/PlGF ratio (4.2 [IQR 3.1–6.3] vs. 5.0 [IQR 3.6–6.9], p = 0.001) was found. No differences in sFlt‐1 concentrations were observed. Higher PlGF concentrations were significantly associated with coronary atherosclerosis; however, associations were attenuated in adjusted analysis. Conclusions: This is the first large study to investigate long‐term differences in circulating angiogenic biomarker concentrations after preeclampsia, highlighting the complex relationship between angiogenic biomarkers, preeclampsia, and later atherosclerotic burden.